Skip to content
Open access

Conformation-specific anti-pathological tau antibody raised against AD brain-derived seed-competent tau reduces tau pathology in transgenic mice

Sep 2026 · Molecular Neurodegeneration Advances · Vol 2 · 0 citations · 53 references

TL;DR

It is revealed that only a low abundant and rare subset of tau species is involved in seeding activity and that this species can be used to raise a conformation- and pathology-specific-antibody against tau.

Abstract

Accumulation of intracellular hyperphosphorylated tau protein into aggregates called neurofibrillary tangles is a hallmark of Alzheimer’s disease (AD) and other neurodegenerative diseases. In AD, tau pathology spreads trans-synaptically in a defined pattern, correlating with cognitive decline. We hypothesized that antibodies targeting the tau species responsible for propagation could slow disease progression. However, the identity of these pathogenic tau species remains unclear. We isolated tau species from AD brain tissue using sucrose gradient fractionation and size-exclusion chromatography (SEC) and developed Single Molecule Array (SIMOA) assays to quantify phosphorylated and aggregated tau in each fraction. To evaluate tau species that are competent seeds for initiating tau aggregation, all sucrose fractions were assessed in human embryonic kidney (HEK) biosensor and primary neuronal seeding assays and evaluated in rTg4510 seeding mouse model. Based on their seeding activity, a panel of antibodies was raised against tau species from the 30–50% fractions and characterized in vitro and in vivo assays. Seeding activity was induced in HEK-biosensor cells and primary neurons with 20–50% AD sucrose fractions, but not by non-AD control fractions. No seeding activity was observed with 0% AD fractions. Furthermore, size exclusive chromatography revealed that seeding activity was induced mainly by tau in high-molecular-weight fractions. A mouse immunization campaign with 30–50% AD sucrose fractions containing seeding competent tau species resulted in a novel anti-pathological tau antibody 008 (APTA-008) that selectively recognizes a pathology-specific conformation of tau. In the rTg4510 in vivo tau seeding model, APTA-008 dosed at 10 mg/kg, significantly reduced tau pathology induced by hippocampal injection of AD brain lysate. Our findings reveal that only a low abundant and rare subset of tau species is involved in seeding activity and that this species can be used to raise a conformation- and pathology-specific-antibody against tau. The discovery of APTA-008 offers a promising therapeutic approach for AD and related tauopathies.

Read PDF

Similar papers

Open access Aug 2026

Amplification of seeding-competent tau aggregates by PMCA in human and experimental tauopathies

Protein misfolding cyclic amplification (PMCA) is established as an in vitro model for studying the seeded aggregation of tau assemblies, providing a powerful tool to advance research into tau aggregation mechanisms and the development of therapeutic interventions.

Florian Almela, M. Bélondrade, R. Caillierez et al. · 0 citations
Review Open access Sep 2026

From seeds to symptoms: the molecular landscape of tau seeding in Alzheimer’s disease

Recent progress in tau seeding research is summarized, highlighting both intrinsic and extrinsic regulators of tau prion-like activity and therapeutic strategies targeting tau pathology.

Jin Miao, Chun-Hong Xue, Xu Yan et al. · 0 citations
Review Open access Aug 2026

Tau Protein Pathology and Tau-Targeted Therapeutic Strategies in Alzheimer’s Disease: Mechanisms, Clinical Evidence and Future Perspectives

Though no tau-targeted therapy has yet to demonstrate definitive clinical benefit, continued research supports tau as an important therapeutic target and contributes to the development of more effective treatments for AD.

Zhuo-Yu Wang · 0 citations
Open access Sep 2026

A scalable human neuron model of Alzheimer’s disease relevant tauopathy reveals mechanisms linking Tau fibrillization to synaptic dysfunction

The development of scalable iPSC-neuron models enables tauopathy drug discovery and reconstructs progressive Tau seeding, fibrillization and synaptic dysfunction, and establishes a physiologically relevant, scalable platform for therapeutic screening that connects Tau seed uptake, site-specific phosphorylation, fibril...

J. Lipka, Xiwei Shan, Qiao Zhang et al. · 0 citations
Open access Sep 2026

Attenuation of Tau-Mediated β-Amyloid1-42 Aggregation by Native PLGA Nanoparticles and Its Relevance to Alzheimer Disease Pathology

Alzheimer’s disease (AD) is an unremitting neurodegenerative disorder characterized by the presence of extracellular β-amyloid (Aβ)-containing neuritic plaques, intracellular tau-positive neurofibrillary tangles and loss of selected neurons in the brain. Evidence suggests that aggregation of Aβ and tau via synergistic...

P. Paul, Aliza Borenstein-Katz, Klinton Shmeit et al. · 0 citations
Review Aug 2026

Tau dysfunction in alzheimer’s disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives

Findings support a model in which tau dysfunction results from the convergence of molecular aberrations and genetic susceptibility within a pathological network involving amyloid-β, neuroinflammation, and synaptic failure.

S. Sura, S. Jagadeesan, M. A. M. Moklas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.